DrugDashboards

Fosaprepitant Dimeglumine

Fosaprepitant Dimeglumine · FOSAPREPITANT DIMEGLUMINE 150 mg/5mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Qilu Pharmaceutical Co., Ltd.

NDC 67184-0540-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $191.78 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA213106
TE code
AP
Approval date
Sep 8, 2020
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Fosaprepitant Dimeglumine (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Avenacy, LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
BluePoint LaboratoriesFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Eugia US LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Merck Sharp & Dohme LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
NorthStar RxLLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Qilu Pharmaceutical Co., Ltd.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 1, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Fosaprepitant Dimeglumine — NDC 67184-0540-01," retrieved September 3, 2026, https://drugdashboards.com/drug/67184054001.

Free to cite with attribution — see how the data is put together.